Cargando…
Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with a median survival of 15 months that has remained unchanged despite advances in the standard of care. GBM cells express human cytomegalovirus (HCMV) proteins, providing a unique opportunity for targeted therapy. We utilized our...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149224/ https://www.ncbi.nlm.nih.gov/pubmed/35651802 http://dx.doi.org/10.3389/fonc.2022.850546 |
_version_ | 1784717161596452864 |
---|---|
author | Adhikari, Amit S. Macauley, Juliete Johnson, Yoshimi Connolly, Mike Coleman, Timothy Heiland, Teri |
author_facet | Adhikari, Amit S. Macauley, Juliete Johnson, Yoshimi Connolly, Mike Coleman, Timothy Heiland, Teri |
author_sort | Adhikari, Amit S. |
collection | PubMed |
description | Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with a median survival of 15 months that has remained unchanged despite advances in the standard of care. GBM cells express human cytomegalovirus (HCMV) proteins, providing a unique opportunity for targeted therapy. We utilized our UNITE (UNiversal Intracellular Targeted Expression) platform to develop a multi-antigen DNA vaccine (ITI-1001) that codes for the HCMV proteins pp65, gB, and IE-1. The UNITE platform involves lysosomal targeting technology, fusing lysosome-associated membrane protein 1 (LAMP1) with target ntigens. We demonstrate evidence of increased antigen presentation by both MHC-I and -II, delivering a robust antigen-specific CD4 and CD8 T-cell response in addition to a strong humoral response. Using a syngeneic orthotopic GBM mouse model, therapeutic treatment with the ITI-1001 vaccine resulted in ~56% survival of tumor-bearing mice. Investigation of the tumor microenvironment showed significant CD4 infiltration as well as enhanced Th1 and cytotoxic CD8 T activation. Regulatory T cells were also upregulated after ITI-1001 vaccination. In addition, tumor burden negatively correlated with activated interferon (IFN)γ+ CD4 T cells, reiterating the importance of CD4 activation in ITI-1001 efficacy and in identifying treatment responders and non-responders. Further characterization of these two groups showed high infiltration of CD3+, CD4+, and CD8+ T cells in responders compared to non-responders. Thus, we show that vaccination with HCMV antigens using the ITI-1001-UNITE platform generates strong cellular and humoral immune responses, triggering significant antitumor activity, leading to enhanced survival in a mouse model of GBM. |
format | Online Article Text |
id | pubmed-9149224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91492242022-05-31 Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform Adhikari, Amit S. Macauley, Juliete Johnson, Yoshimi Connolly, Mike Coleman, Timothy Heiland, Teri Front Oncol Oncology Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with a median survival of 15 months that has remained unchanged despite advances in the standard of care. GBM cells express human cytomegalovirus (HCMV) proteins, providing a unique opportunity for targeted therapy. We utilized our UNITE (UNiversal Intracellular Targeted Expression) platform to develop a multi-antigen DNA vaccine (ITI-1001) that codes for the HCMV proteins pp65, gB, and IE-1. The UNITE platform involves lysosomal targeting technology, fusing lysosome-associated membrane protein 1 (LAMP1) with target ntigens. We demonstrate evidence of increased antigen presentation by both MHC-I and -II, delivering a robust antigen-specific CD4 and CD8 T-cell response in addition to a strong humoral response. Using a syngeneic orthotopic GBM mouse model, therapeutic treatment with the ITI-1001 vaccine resulted in ~56% survival of tumor-bearing mice. Investigation of the tumor microenvironment showed significant CD4 infiltration as well as enhanced Th1 and cytotoxic CD8 T activation. Regulatory T cells were also upregulated after ITI-1001 vaccination. In addition, tumor burden negatively correlated with activated interferon (IFN)γ+ CD4 T cells, reiterating the importance of CD4 activation in ITI-1001 efficacy and in identifying treatment responders and non-responders. Further characterization of these two groups showed high infiltration of CD3+, CD4+, and CD8+ T cells in responders compared to non-responders. Thus, we show that vaccination with HCMV antigens using the ITI-1001-UNITE platform generates strong cellular and humoral immune responses, triggering significant antitumor activity, leading to enhanced survival in a mouse model of GBM. Frontiers Media S.A. 2022-05-16 /pmc/articles/PMC9149224/ /pubmed/35651802 http://dx.doi.org/10.3389/fonc.2022.850546 Text en Copyright © 2022 Adhikari, Macauley, Johnson, Connolly, Coleman and Heiland https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Adhikari, Amit S. Macauley, Juliete Johnson, Yoshimi Connolly, Mike Coleman, Timothy Heiland, Teri Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform |
title | Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform |
title_full | Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform |
title_fullStr | Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform |
title_full_unstemmed | Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform |
title_short | Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform |
title_sort | development and characterization of an hcmv multi-antigen therapeutic vaccine for glioblastoma using the unite platform |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149224/ https://www.ncbi.nlm.nih.gov/pubmed/35651802 http://dx.doi.org/10.3389/fonc.2022.850546 |
work_keys_str_mv | AT adhikariamits developmentandcharacterizationofanhcmvmultiantigentherapeuticvaccineforglioblastomausingtheuniteplatform AT macauleyjuliete developmentandcharacterizationofanhcmvmultiantigentherapeuticvaccineforglioblastomausingtheuniteplatform AT johnsonyoshimi developmentandcharacterizationofanhcmvmultiantigentherapeuticvaccineforglioblastomausingtheuniteplatform AT connollymike developmentandcharacterizationofanhcmvmultiantigentherapeuticvaccineforglioblastomausingtheuniteplatform AT colemantimothy developmentandcharacterizationofanhcmvmultiantigentherapeuticvaccineforglioblastomausingtheuniteplatform AT heilandteri developmentandcharacterizationofanhcmvmultiantigentherapeuticvaccineforglioblastomausingtheuniteplatform |